Common TitleTRANxITION
Official Title An Open Label, Phase IIIb, Randomised Parallel Group Study to Assess the Efficacy and Safety of Switching HIV-1 Infected Patients Successfully Treated With a Nevirapine IR Based Regiment to Nevirapine XR 400 mg QD or Remaining on Nevirapine IR 200 mg BID Based Program
Phase Phase IIIB
ClinicalTrials.gov NCT00819052
Treatments
Nevirapine
Nevirapine
Tradename:ViramuneOther Names:NVPClass:Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)Categories Treatment-ExperiencedSwitch/Simplification
Funding
IndustryBoehringer Ingelheim
References
- Arasteh K, Ward D, Plettenberg A, et al. Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION). HIV Med. 2012;13:236-44.